Broadcom named strategic vendor for Walmart virtualization solutions
On Monday, KeyBanc Capital Markets maintained a positive outlook on Lonza Group AG (LONN:SW) (OTC: LZAGY), reiterating an Overweight rating and a price target of CHF610.00. KeyBanc highlighted Lonza's potential for high growth by 2025 compared to its large-cap life science peers. According to KeyBanc, Lonza boasts a growth rate two to three times faster than its competitors, with a forecasted low-teens growth rate and a forward FY26 enterprise value to earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) multiple of 16.0x. This valuation is notably lower than those of its industry peers.
Lonza, recognized as the world's largest contract development and manufacturing organization (CDMO), has stood out with its recent guidance for the year 2025. The company anticipates low-teens organic growth on its core business, aligning with its long-term targets. Furthermore, Lonza is expected to benefit from various strategies to expand its margins, with management indicating that EBITDA margin on the core business could approach 30%.
Over the past nine months, Lonza's stock has fluctuated between approximately CHF 470 and CHF 590. KeyBanc attributes this volatility to factors such as the diminishing COVID-19 revenue, challenges within the Chemical and Ingredients (CHI) business, which is currently being divested, and a transition in the company's CEO. With these uncertainties now resolved, KeyBanc anticipates that Lonza's stock has the potential to surge and narrow the valuation disparity with its peers.
The firm's optimistic stance on Lonza is based on the company's robust growth trajectory and its strategic position within the life sciences sector. As the industry continues to evolve, Lonza's focus on core business growth and margin expansion is expected to drive its performance in the upcoming years.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.